SecBot SecBot
PRESS-RELEASE ·Filed Apr 3, 2026

BCAX

Bicara Therapeutics Inc.
NEUTRAL
Impact 2/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

Monitor for additional inducement grants or insider activity; this isolated grant is routine for biotech firms and unlikely to move the stock. However, recent insider selling of $305K over 30 days may signal caution.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$20.85
T+0 close · Apr 3, 2026 · via day close
Latest settled
+38.66%
T+60 · $28.91
Vs SPY
+25.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $20.85entry
  2. T+1 · 7mo ago +2.11%α +2.05% · $21.29
  3. T+5 · 7mo ago +6.19%α +2.05% · $22.14
  4. T+20 · 7mo ago +8.97%α −0.01% · $22.72
  5. T+60 · 5mo ago +38.66%α +25.19% · $28.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bicara Therapeutics granted a stock option to purchase 44,175 shares to a new employee as an inducement to join the company. The award was made outside of its shareholder-approved plans under the 2026 Inducement Plan, consistent with Nasdaq rules.

Key Facts

  • Bicara Therapeutics granted a non-qualified stock option to purchase 44,175 shares to a new employee on April 1, 2026.
  • The option has an exercise price of $20.50 per share, equal to the closing price on the grant date.
  • Vesting: 25% on first anniversary, remaining 75% over 12 equal quarterly installments.
  • Grant made under the 2026 Inducement Plan, approved by independent directors, outside shareholder-approved equity plans.
  • No financial metrics, revenue, or earnings impact disclosed.

Financial Impact

Minimal near-term financial impact; potential for minor dilution from 44,175 shares.

dilutionshare_count

Risk Factors

  • Potential for incremental dilution if multiple such grants occur.
  • Insider selling trend may contrast with positive messaging around hiring.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3267999

Track record

26 reports on BCAX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
  2. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  3. Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  4. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
  5. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
  7. Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
  8. Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
  9. Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (10h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026